Ranbaxy Laboratories is currently trading at Rs. 512.40, up by 11.05 points or 2.20% from its previous closing of Rs. 501.35 on the BSE.

The scrip opened at Rs. 500.50 and has touched a high and low of Rs. 515.50 and Rs. 495.10 respectively. So far 121464 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 555.00 on 04-Aug-2011 and a 52 week low of Rs. 366.50 on 19-Dec-2011.

Last one week high and low of the scrip stood at Rs. 515.50 and Rs. 485.20 respectively. The current market cap of the company is Rs. 21552.40 crore.

The promoters holding in the company stood at 63.66% while Institutions and Non-Institutions held 20.74% and 13.61% respectively.

Ranbaxy Laboratories has entered into an in-licensing agreement with Gilead Sciences to promote access to high quality, low cost generic versions of Gilead's HIV medicine emtricitabine in developing countries, including single tablet regimes containing emtricitabine and fixed close combinations of emtricitabine co-formulated with other Gilead IIIV medicines.

Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.